Kiora Pharmaceuticals (KPRX) Interest & Investment Income (2014 - 2022)
Kiora Pharmaceuticals' (KPRX) quarterly Interest & Investment Income came in at $1237.0 in Q2 2022, up 272.59% YoY from $332.0 in Q2 2021, and up 470.05% on a QoQ basis from $217.0 in Q1 2022.
Kiora Pharmaceuticals (KPRX) Interest & Investment Income (2014 - 2022) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 9 years of Interest & Investment Income data on file, last reported at $1237.0 in Q2 2022.
- Quarterly Interest & Investment Income rose 272.59% year-over-year to $1237.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $2013.0 (up 77.04% YoY) and the FY2025 annual result came in at $894002.0, down 28.64% from the prior year.
- Interest & Investment Income climbed to $1237.0 in Q2 2022, from $217.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $54346.0 in Q3 2018 to a low of $26.0 in Q1 2018.
- A 5-year average of $14131.3 and a median of $2788.5 in 2020 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2018 — Interest & Investment Income jumped 176285.19% — and 2021, when it plunged 98.64%.
- Tracing KPRX's Interest & Investment Income over 5 years: stood at $47624.0 in 2018, then plunged by 78.67% to $10157.0 in 2019, then sank by 97.79% to $224.0 in 2020, then soared by 33.93% to $300.0 in 2021, then surged by 312.33% to $1237.0 in 2022.
- The last three Interest & Investment Income figures came in at $1237.0 (Q2 2022), $217.0 (Q1 2022), and $300.0 (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 28.14 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 10.98 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 5.13 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 115.94 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 146,232.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 1,237.00 |
| Mar 31, 2022 | 217.00 |
| Dec 31, 2021 | 300.00 |
| Sep 30, 2021 | 259.00 |
| Jun 30, 2021 | 332.00 |
| Mar 31, 2021 | 250.00 |
| Dec 31, 2020 | 224.00 |
| Sep 30, 2020 | 331.00 |
| Jun 30, 2020 | 4,340.00 |
| Mar 31, 2020 | 18,444.00 |
| Dec 31, 2019 | 10,157.00 |
| Sep 30, 2019 | 22,996.00 |
| Jun 30, 2019 | 32,636.00 |
| Mar 31, 2019 | 42,277.00 |
| Dec 31, 2018 | 47,624.00 |
| Sep 30, 2018 | 54,346.00 |
| Jun 30, 2018 | 18,367.00 |
| Mar 31, 2018 | 26.00 |
| Dec 31, 2017 | 27.00 |
| Sep 30, 2017 | 40.00 |